NDA 207070 · Boehringer Ingelheim
Spiriva Respimat
Tiotropium Bromide · Inhalation
Last checked: Nov 20, 2026Latest source record: Sep 15, 2015 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2015
Sep 15, 2015
Approved uses
1
Original approval plus efficacy supplements
Registered trials
347
124 Phase 3, 2 recruiting
FAERS reports
11,487
6,855 serious, 778 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Aug 17, 2026.
SPIRIVA RESPIMAT is an anticholinergic indicated for: The long-term, once-daily, maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), and for reducing COPD exacerbations ( 1.1 ) The long-term, once-daily, maintenance treatment of asthma in patients 6 years of age and older ( 1.2 ) Limitation of Use: Not indicated for relief of acute bronchospasm ( 1.1 , 1.2 , 5.1 ) 1.1 Maintenance Treatment of Chronic Obstructive Pulmonary Disease SPIRIVA RESPIMAT (tiotropium bromide) is indicated for the long-term, once-daily, maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. SPIRIVA RESPIMAT is indicated to reduce exacerbations in COPD patients. Important Limitation of Use: SPIRIVA RESPIMAT is NOT indicated for the relief of acute bronchospasm. 1.2 Maintenance Treatment of Asthma SPIRIVA RESPIMAT is a bronchodilator indicated for the long-term, once-daily, maintenance treatment of asthma in patients 6 years of age and older . Important Limitation of Use: SPIRIVA RESPIMAT is NOT indicated for the relief of acute bronchospasm.
Mechanism: Tiotropium is a long-acting, antimuscarinic agent, which is often referred to as an anticholinergic. It has similar affinity to the subtypes of muscarinic receptors, M 1 to M 5 . In the airways, it exhibits pharmacological effects through inhibition of M 3 -receptors at the smooth muscle leading to bronchodilation. The competitive and reversible nature of antagonism was shown with human and animal origin receptors and isolated organ preparations. In preclinical in vitro as well as in vivo studies, prevention of methacholine-induced bronchoconstriction effects was dose-dependent and lasted...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Sep 15, 2015 Original approval · Type 9 - New Indication Submitted as Distinct NDA, Consolidated with Original NDA after Approval LabelPediatric Medical ReviewPediatric Medical Addendum
1 products under this application
- SPIRIVA RESPIMAT · TIOTROPIUM BROMIDE 2.5MCG · SPRAY, INHALATION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Tiotropium" as an intervention, any sponsor and status, largest first.
- Comparison of Tiotropium in the HandiHaler Versus the Respimat in Chronic Obstructive Pulmonary DiseasePivotal-lookingCompleted
Boehringer IngelheimBoehringer Ingelheim
NCT01126437 · 17,183 participants · Start May 2010 · Primary completion May 2013
Drug: tiotropium 18 mcg; tiotropium 1.25 mcg (2 actuations/day) and 1 more · For: Pulmonary Disease, Chronic Obstructive
Sites: Athens, Alabama; Birmingham, Alabama; Florence, Alabama · 1,191 sites in all
Boehringer IngelheimBoehringer Ingelheim
NCT02296138 · 7,903 participants · Start Jan 13, 2015 · Primary completion Mar 8, 2017
Drug: olodaterol; tiotropium and 1 more · For: Pulmonary Disease, Chronic Obstructive
Sites: Andalusia, Alabama; Birmingham, Alabama; Florence, Alabama · 818 sites in all
- Tiotropium Once Daily 18 Mcg Versus Salmeterol Twice Daily 50 Mcg on Time to First Exacerbation in COPD Patients.Pivotal-lookingCompleted
Boehringer IngelheimBoehringer Ingelheim
NCT00563381 · 7,376 participants · Start Jan 2008 · Primary completion Apr 2010
Drug: Tiotropium bromide; Salmeterol and 2 more · For: Pulmonary Disease, Chronic Obstructive
Sites: Feldbach, Austria; Feldkirch, Austria; Gänserndorf, Austria · 752 sites in all
- Evaluation of the Long- Term Effects of Spiriva on Lung Function in COPD PatientsPivotal-lookingCompleted
Boehringer IngelheimBoehringer Ingelheim
NCT00144339 · 5,993 participants · Start Dec 2002 · Primary completion Feb 2008
Drug: tiotropium; placebo · For: Pulmonary Disease, Chronic Obstructive
Sites: Anniston, Alabama; Birmingham, Alabama; Jasper, Alabama · 490 sites in all
- Tiotropium / Respimat One Year Study in COPD.Pivotal-lookingCompleted
Boehringer IngelheimBoehringer Ingelheim
NCT00387088 · 3,991 participants · Start Sep 2006 · Primary completion Jan 2009
Drug: Tiotropium · For: Pulmonary Disease, Chronic Obstructive
Sites: Birmingham, Alabama; Mobile, Alabama; Berkeley, California · 334 sites in all
- Efficacy of Fixed Combination of Beclometasone + Formoterol + Glycopyrrolate in Chronic Obstructive Pulmonary DiseasePivotal-lookingCompleted
Chiesi Farmaceutici S.p.A.Industry
NCT01911364 · 3,686 participants · Start Jan 2014 · Primary completion Mar 2016
Drug: BDP/FF/GB; Tiotropium and 1 more · For: Chronic Obstructive Pulmonary Disease
Sites: Hessen, Germany; Szeged, Hungary; Perugia, Italy
- Exacerbation StudyPivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT00845728 · 3,439 participants · Start Mar 2009 · Primary completion Jul 2012
Drug: Indacaterol 150 µg; Tiotropium · For: Chronic Obstructive Pulmonary Disease
Sites: Buenos Aires, Argentina; Capital Federal, Argentina; Mar del Plata, Argentina · 423 sites in all
- Tiotropium+Olodaterol Fixed Dose Combination (FDC) Versus Tiotropium and Olodaterol in Chronic Obstructive Pulmonary Disease (COPD)Pivotal-lookingCompleted
Boehringer IngelheimBoehringer Ingelheim
NCT01431274 · 2,624 participants · Start Sep 2011 · Primary completion Sep 2013
Drug: tiotropium + olodaterol; tiotropium and 3 more · For: Pulmonary Disease, Chronic Obstructive
Sites: Jasper, Alabama; Mobile, Alabama; Boulder, Colorado · 239 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- dyspnoea2,340
- asthma1,510
- cough1,093
- pneumonia934
- wheezing846
- drug ineffective771
- off label use716
- therapeutic product effect incomplete581
- chronic obstructive pulmonary disease570
- loss of personal independence in daily activities520
- fatigue508
- headache469
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2008 | 3 |
| 2009 | 3 |
| 2010 | 13 |
| 2011 | 24 |
| 2012 | 42 |
| 2013 | 75 |
| 2014 | 31 |
| 2015 | 50 |
| 2016 | 121 |
| 2017 | 418 |
| 2018 | 1,080 |
| 2019 | 1,223 |
| 2020 | 1,652 |
| 2021 | 1,213 |
| 2022 | 1,006 |
| 2023 | 1,000 |
| 2024 | 1,273 |
| 2025 | 1,209 |
| 2026 | 1,051 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Spiriva Respimat (Tiotropium Bromide)
2024 spending
$877M
Beneficiaries
327,575
1,276,042 claims
Per beneficiary
$2,678
$119.52 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $804,565,194 |
| 2021 | $856,830,826 |
| 2022 | $891,532,179 |
| 2023 | $923,556,171 |
| 2024 | $877,208,066 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Long-term safety of tiotropium/olodaterol in older patients with moderate-to-very-severe COPD in the TONADO® studies.
Ferguson GT, Maltais F, Karpel J, et al. · NPJ Prim Care Respir Med 2020 · Clinical Trial, Phase III, Randomized Controlled Trial
- Systematic literature review and meta-analysis of US-approved LAMA/LABA therapies versus tiotropium in moderate-to-severe COPD.
Han MK, Ray R, Foo J, et al. · NPJ Prim Care Respir Med 2018 · Comparative Study, Meta-Analysis
- β-Blockers in COPD: A Cohort Study From the TONADO Research Program.
Maltais F, Buhl R, Koch A, et al. · Chest 2018 · Clinical Trial, Phase III, Multicenter Study
- Tiotropium in Early-Stage Chronic Obstructive Pulmonary Disease.
Zhou Y, Zhong NS, Li X, et al. · N Engl J Med 2017 · Clinical Trial, Phase IV, Multicenter Study
- Tiotropium reduces airflow obstruction in asthma patients, independent of body mass index.
Khurana S, Paggiaro P, Buhl R, et al. · J Allergy Clin Immunol Pract 2019 · Clinical Trial, Phase III, Letter
- A systematic review of comparative studies of tiotropium Respimat® and tiotropium HandiHaler® in patients with chronic obstructive pulmonary disease: does inhaler choice matter?
Dahl R, Kaplan A · BMC Pulm Med 2016 · Systematic Review
Sponsor: Boehringer Ingelheim
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.